Cocoon Biosciences, a spinoff of Algenex (a Spanish biotech company acquired by Insud Pharma), develops high-performance growth factors for the alternative protein industry, including cultivated meat using caterpillar loopers as bioreactors. The company claims this method is a lower-cost production approach over traditional bioreactor-based production. It operates the CrisBio platform, which utilizes insects as natural, single-use bioreactors. The platform produces multiple growth factors for cultivated meat, including FGF2, PDGF, EGF, and TGF-B1 (in active development).
The company plans to build a production facility in Bilbao, Spain, capable of producing up to kilograms of growth factors per year for alternative proteins and is expected to be fully operational in 2024.
Funding and financials
In March 2023, Cocoon Biosciences closed a EUR 15 million (~USD 15.9 million) funding round. The round was led by Columbus Venture Partners and Cleon Capital, with participation from Viscofan, North-South Ventures, and others. The funds were earmarked to scale its business and build its upcoming production facilities.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.